461 related articles for article (PubMed ID: 26554946)
1. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
2. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
3. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Premnath PN; Craig SN; Liu S; McInnes C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
[TBL] [Abstract][Full Text] [Related]
4. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
5. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
6. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Zheleva DI; McInnes C; Gavine AL; Zhelev NZ; Fischer PM; Lane DP
J Pept Res; 2002 Nov; 60(5):257-70. PubMed ID: 12383116
[TBL] [Abstract][Full Text] [Related]
7. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
8. Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.
Premnath PN; Liu S; Perkins T; Abbott J; Anderson E; McInnes C
Bioorg Med Chem; 2014 Jan; 22(1):616-22. PubMed ID: 24286762
[TBL] [Abstract][Full Text] [Related]
9. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
10. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
Arumugasamy K; Tripathi SK; Singh P; Singh SK
Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
[TBL] [Abstract][Full Text] [Related]
11. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
Brown NR; Korolchuk S; Martin MP; Stanley WA; Moukhametzianov R; Noble MEM; Endicott JA
Nat Commun; 2015 Apr; 6():6769. PubMed ID: 25864384
[TBL] [Abstract][Full Text] [Related]
12. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
Andrews MJ; Kontopidis G; McInnes C; Plater A; Innes L; Cowan A; Jewsbury P; Fischer PM
Chembiochem; 2006 Dec; 7(12):1909-15. PubMed ID: 17051658
[TBL] [Abstract][Full Text] [Related]
13. Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.
Liu S; Premnath PN; Bolger JK; Perkins TL; Kirkland LO; Kontopidis G; McInnes C
J Med Chem; 2013 Feb; 56(4):1573-82. PubMed ID: 23323521
[TBL] [Abstract][Full Text] [Related]
14. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
Canela N; Orzáez M; Fucho R; Mateo F; Gutierrez R; Pineda-Lucena A; Bachs O; Pérez-Payá E
J Biol Chem; 2006 Nov; 281(47):35942-53. PubMed ID: 17001081
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
16. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
17. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
18. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]